EUVIMEDSkopri EUVIMED
KohortenstudieOpen access · CC BY-NC-ND 4.0

Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort study

Hamlet Gasoyan iD, Elizabeth R Pfoh, Rebecca Schulte, Phuc Le, Michael B Rothberg

Obesity · 2024-03 · 32 (3) · 486-493

DOI: 10.1002/oby.23952 ↗

At a glance

Kohortenstudie in Obesity, published online on 2023-12-06. Written by Hamlet Gasoyan and 4 co-authors. Institution: Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA. Major MEDLINE topics: Anti-Obesity Agents. Cited 98 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCI NIH HHS, National Cancer Institute.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

The study's objective was to examine the percentage of patients with an initial antiobesity medication (AOM) fill who were persistent with AOM at 3, 6, and 12 months and to characterize factors associated with persistence at 12 months.

Methods

This retrospective cohort study used electronic health records from January 2015 to July 2023 in a large health system in Ohio and Florida and included adults with BMI ≥30 kg/m 2 who had an initial AOM prescription filled between 2015 and 2022.

Results

The authors identified 1911 patients with a median baseline BMI of 38 (IQR, 34–44). Over time, 44% were persistent with AOM at 3 months, 33% at 6 months, and 19% at 12 months. Across categories of AOM, the highest 1‐year persistence was in patients receiving semaglutide (40%). Semaglutide (adjusted odds ratio [AOR] = 4.26, 95% CI: 3.04–6.05) was associated with higher odds of 1‐year persistence, and naltrexone‐bupropion (AOR = 0.68, 95% CI: 0.46–1.00) was associated with lower odds, compared with phentermine‐topiramate. Among patients who were persistent at 6 months, a 1% increase in weight loss at 6 months was associated with 6% increased odds of persistence at year 1 (AOR = 1.06, 95% CI: 1.03–1.09).

Conclusions

Later‐stage persistence with AOM varies considerably based on the drug and the weight loss at 6 months.

Subjects

MeSH terms (MEDLINE)

Anti-Obesity AgentsAdultHumansRetrospective StudiesWeight LossOhio

Substances

Anti-Obesity Agents

Authors and institutions

  • Center for Value-Based Care Research, Department of Internal Medicine and Geriatrics, Primary Care Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
  • Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID profiles: Hamlet Gasoyan

Funding

  • NCI NIH HHS
  • National Cancer Institute

Cite

APA

Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P., & Rothberg, M. B. (2024). Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort study. Obesity, 32(3), 486-493. https://doi.org/10.1002/oby.23952

Vancouver

Gasoyan H, Pfoh ER, Schulte R, Le P, Rothberg MB. Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort study. Obesity. 2024;32(3):486-493. doi:10.1002/oby.23952

BibTeX
@article{Gasoyan2024,
  author = {Gasoyan, Hamlet and Pfoh, Elizabeth R and Schulte, Rebecca and Le, Phuc and Rothberg, Michael B},
  title = {Early‐ and later‐stage persistence with antiobesity medications: A retrospective cohort study},
  journal = {Obesity},
  year = {2024},
  volume = {32},
  number = {3},
  pages = {486--493},
  doi = {10.1002/oby.23952}
}
Start for free →